LifeScreen has developed a skin-based test that provides quantitative prognostic values on an individual’s rate of aging and are therefore highly predictive of age-associated health risks. Our novel biomarkers reflect the cell’s metabolic state, which is highly integrated with the aging process. Our solution provides the ability to provide a dynamic measure of health that can be re-assessed following specific interventions, and potentially provide recommendations on how to further improve health. We can develop our technology into a diagnostic tool for use in hospitals and clinics, as well as a drug discovery platform for companies pursuing anti-aging research. Currently, we have validated our biomarker as a cancer prognostic that accurately predicts the age of cancer onset (i.e., when tumours will likely develop) for predisposed individuals.